Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7366 to 7380 of 7710 results

  1. TriageHF Plus for remotely monitoring people with cardiac implantable electronic devices at risk of heart failure or worsening heart failure (MIB298)

    This medtech innovation briefing has been replaced by NICE diagnostic guidance on heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices.

    Medtech innovation briefing
    Published
    31 May 2022

  2. Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy (ES20)

    This evidence summary has been updated and replaced by NICE guideline NG201.

    Evidence summary
    Published
    24 June 2019

  3. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]

    In development [GID-TA10726] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Head injury: assessment and early management (CG176)

    This guideline has been updated and replaced by the NICE guideline on head injury: assessment and management (NG232).

    Clinical guideline
    Last updated
    13 September 2019

  5. Etanercept and infliximab for the treatment of psoriatic arthritis (TA104)

    This guidance has been replaced by NICE technology appraisal guidance 199.

    Technology appraisal guidance
    Published
    26 July 2006

  6. Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]

    Discontinued [GID-TA10869]

    Technology appraisal guidance
    Discontinued

  7. Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]

    In development [GID-TA11273] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Difficult-to-treat scabies: oral ivermectin (ESUOM29)

    November 2024: This evidence summary has been withdrawn because licensed products are now available.

    Evidence summary
    Published
    18 March 2014

  9. Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]

    Discontinued [GID-TA10996]

    Technology appraisal guidance
    Discontinued

  10. Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]

    Discontinued [GID-TA10995]

    Technology appraisal guidance
    Discontinued

  11. Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]

    Discontinued [GID-TA11108]

    Technology appraisal guidance
    Discontinued

  12. Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058]

    Discontinued [GID-TA10937]

    Technology appraisal guidance
    Discontinued

  13. Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205]

    Discontinued [GID-TA10965]

    Technology appraisal guidance
    Discontinued

  14. Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]

    Discontinued [GID-TA10863]

    Technology appraisal guidance
    Discontinued

  15. Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]

    Discontinued [GID-TA10766]

    Technology appraisal guidance
    Discontinued